Best Investments for
Pharmaceutical veteran Carrie Cox was highlighted by TheStreet as a great addition to any board of directors. She shares her thoughts on what it means to be a good director.
Doug Kass invokes Elaine from 'Seinfeld' to describe China's data and finds Starbucks not quite good to the last drop
Jim Cramer looks carefully and prefers the companies over German data, and considers papers and plastics in China.
The San Francisco target rejects the $9.3 billion offer, but biotech growth and a healthy pipeline mean Sanofi isn't desperate for Medivation's cancer treatments.
Benchmark indices slip after better-than-forecast data on first-quarter GDP but disappointing news on Eurozone consumer prices.
The following THERMO FISHER SCIENTIFIC INC (TMO) conference call took place on April 28, 2016, 08:30 AM ET. This is a transcript of that earnings call:
The following BRISTOL-MYERS SQUIBB CO (BMY) conference call took place on April 28, 2016, 10:30 AM ET. This is a transcript of that earnings call:
The following United Therapeutics (UTHR) conference call took place on April 28, 2016, 09:00 AM ET. This is a transcript of that earnings call:
Thursday's parade of deals seem to answer a question that's been bugging health care investors for most of 2016: why haven't retreating biotech valuations sparked an uptick in M&A activity?
Gilead Sciences (GILD) shares are slumping on Thursday morning ahead of the company's 2016 first quarter results set to be released this afternoon.
Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.
The following Vertex Pharmaceuticals (VRTX) conference call took place on April 27, 2016, 05:30 PM ET. This is a transcript of that earnings call:
The French pharmaceuticals company takes its campaign to snare the oncology specialist public.
Deutsche Bank jumps on brighter-than-expected first-quarter numbers but the prospect of order delays grounds shares in Airbus.
Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.